You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 科濟藥業-B漲5% 公佈兩項關於治療多發性骨髓瘤藥物“CT053”研究結果
格隆匯 12-13 13:37
格隆匯12月13日丨科濟藥業-B(2171.HK)現漲5.11%,報43.2港元,總市值245億港元。科濟藥業-B今日發佈公吿,在2021年美國血液學會(“ASH”)年會上,公司展示了兩篇關於CT053(一種靶向BCMA的自體CAR T細胞候選產品)研究結果的海報,其包含了(1)一項在中國開展的I/II期研究(LUMMICAR-1)的持續有效性和安全性結果,和(2)在復發╱難治性多發性骨髓瘤(R/R MM)受試者中的高危因素彙總分析。結果表明,CT053在復發/難治多發性骨髓瘤患者(50%的患者具有高危細胞遺傳學異常)中提供深度且持久的療效反應,且總體耐受性良好。而CT053在復發/難治多發性骨髓瘤患者中(包括高危人羣)是一種具有前景的治療手段,且總體耐受性良好。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account